Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer

[1]  Young Hun Kim,et al.  Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs. , 2015, International journal of pharmaceutics.

[2]  Y. Oh,et al.  Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation , 2015, International journal of nanomedicine.

[3]  Clive G. Wilson,et al.  Statistical investigation of simulated intestinal fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  Han‐Gon Choi,et al.  Preparation and Characterization of Fenofibrate-Loaded Nanostructured Lipid Carriers for Oral Bioavailability Enhancement , 2014, AAPS PharmSciTech.

[5]  G. Malhotra,et al.  Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects. , 2014, Clinical therapeutics.

[6]  Han‐Gon Choi,et al.  Application of Box–Behnken design in the preparation and optimization of fenofibrate-loaded self-microemulsifying drug delivery system (SMEDDS) , 2014, Journal of microencapsulation.

[7]  A. Keech,et al.  An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes , 2013, Diabetes.

[8]  Han‐Gon Choi,et al.  Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems , 2013, Drug development and industrial pharmacy.

[9]  Han‐Gon Choi,et al.  Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs , 2013, Drug development and industrial pharmacy.

[10]  D. Hilleman,et al.  A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations , 2013, Cardiology research.

[11]  Han‐Gon Choi,et al.  Fabrication of a uniformly sized fenofibrate microemulsion by membrane emulsification , 2013, Journal of microencapsulation.

[12]  P. Mitchell,et al.  Fenofibrate - a potential systemic treatment for diabetic retinopathy? , 2012, American journal of ophthalmology.

[13]  C. Ballantyne,et al.  Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial , 2012, Cardiovascular Drugs and Therapy.

[14]  K. Pintye-Hódi,et al.  Study of the influence of alkalizing components on matrix pellets prepared by extrusion/spheronization , 2012, Pharmaceutical development and technology.

[15]  R. Simó,et al.  Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate. , 2012, Reviews on recent clinical trials.

[16]  P. Tran,et al.  Investigation of physicochemical factors affecting the stability of a pH-modulated solid dispersion and a tablet during storage. , 2011, International journal of pharmaceutics.

[17]  M. Elisaf,et al.  Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia , 2011, Expert opinion on pharmacotherapy.

[18]  J. Ansquer,et al.  Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans , 2010, Journal of clinical pharmacology.

[19]  P. Alagona.  Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia , 2010, Vascular health and risk management.

[20]  P. Tran,et al.  The roles of acidifiers in solid dispersions and physical mixtures. , 2010, International journal of pharmaceutics.

[21]  D. Bhavesh,et al.  Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. , 2009, Biomedical chromatography : BMC.

[22]  P. Tran,et al.  Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  R. Rosenson.  Fenofibrate: treatment of hyperlipidemia and beyond , 2008, Expert review of cardiovascular therapy.

[24]  Ram B. Gupta,et al.  Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. , 2008, International journal of pharmaceutics.

[25]  Jennifer B Dressman,et al.  Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  G Vergnault,et al.  Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. , 2007, Advanced drug delivery reviews.

[27]  Zhihong Ge,et al.  Real-time endpoint monitoring and determination for a pharmaceutical salt formation process with in-line FT-IR spectroscopy. , 2006, Journal of pharmaceutical and biomedical analysis.

[28]  S. Daskalopoulou,et al.  Fenofibrate: metabolic and pleiotropic effects. , 2005, Current vascular pharmacology.